Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
ALWAYTH x Adidas Samba: Revolutionizing Sneaker Culture with Fashion-Forward Collaboration 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
McDonald's China Faces Backlash for Food Hygiene Violations 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
HAYWARD, Calif., Sept. 05, 2017 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, today announced its participation in the Citi 12th Annual Biotech Conference. Anthera will host meetings at the Citi Biotech Conference in Boston on Thursday, September 7th.
Additional information on Anthera can be found at www.anthera.com
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
Contact Information CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc. [email protected] For Media Inquiries: Srikant Ramaswami rbb Communications [email protected] 718-710-1350
